Pfizer, Inc. (PFE) Shares Sold by Greenleaf Trust

Greenleaf Trust cut its holdings in Pfizer, Inc. (NYSE:PFE) by 0.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 193,517 shares of the biopharmaceutical company’s stock after selling 1,818 shares during the period. Greenleaf Trust’s holdings in Pfizer were worth $6,500,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also bought and sold shares of the company. Fisher Asset Management LLC raised its position in shares of Pfizer by 3.9% in the 2nd quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock worth $1,143,248,000 after acquiring an additional 1,275,832 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Pfizer by 1.2% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 31,260,823 shares of the biopharmaceutical company’s stock worth $1,069,433,000 after acquiring an additional 377,404 shares in the last quarter. Macquarie Group Ltd. raised its position in shares of Pfizer by 0.9% in the 1st quarter. Macquarie Group Ltd. now owns 24,683,746 shares of the biopharmaceutical company’s stock worth $844,431,000 after acquiring an additional 228,405 shares in the last quarter. Boston Partners raised its position in shares of Pfizer by 7.3% in the 1st quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock worth $830,071,000 after acquiring an additional 1,649,801 shares in the last quarter. Finally, Bank of Montreal Can raised its position in shares of Pfizer by 1.2% in the 2nd quarter. Bank of Montreal Can now owns 18,534,159 shares of the biopharmaceutical company’s stock worth $622,562,000 after acquiring an additional 227,682 shares in the last quarter. 69.09% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.chaffeybreeze.com/2017/09/17/pfizer-inc-pfe-shares-sold-by-greenleaf-trust.html.

In other Pfizer news, insider Laurie J. Olson sold 8,064 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $32.70, for a total transaction of $263,692.80. Following the completion of the transaction, the insider now owns 74,506 shares of the company’s stock, valued at $2,436,346.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ian C. Read sold 197,168 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the transaction, the chief executive officer now directly owns 580,318 shares of the company’s stock, valued at approximately $19,730,812. The disclosure for this sale can be found here. Insiders have sold 464,521 shares of company stock valued at $15,813,961 in the last ninety days. Insiders own 0.06% of the company’s stock.

Shares of Pfizer, Inc. (PFE) traded down 1.04% during mid-day trading on Friday, reaching $35.36. The company’s stock had a trading volume of 28,871,059 shares. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $35.84. The company has a 50-day moving average of $33.64 and a 200-day moving average of $33.53. The company has a market cap of $210.30 billion, a P/E ratio of 25.87 and a beta of 1.00.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter last year, the firm earned $0.64 earnings per share. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. Equities research analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 1st. Shareholders of record on Friday, August 4th were paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.62%. The ex-dividend date was Wednesday, August 2nd. Pfizer’s dividend payout ratio is 94.12%.

Several research analysts have recently weighed in on PFE shares. ValuEngine lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Morgan Stanley reissued a “neutral” rating and issued a $35.00 price objective (down from $38.00) on shares of Pfizer in a research report on Monday, June 12th. Jefferies Group LLC reissued a “neutral” rating and issued a $34.00 price objective on shares of Pfizer in a research report on Friday, June 16th. BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. Finally, Cowen and Company set a $43.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Monday, July 10th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $37.72.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply